Author:
Munhoz Rodrigo Ramella,Postow Michael Andrew
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference55 articles.
1. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Nat Rev Clin Oncol,2017
2. Genomic classification of cutaneous melanoma;Cell,2015
3. Improved overall survival in melanoma with combined dabrafenib and trametinib;N Engl J Med,2015
4. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Lancet Oncol,2016
5. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unressectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma;J Clin Oncol,2014
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献